Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records
Our results indicate no significant differences in the incidence of thrombocytopenia and severe anemia between generic and brand-name linezolid, highlighting the need for further validation in other generic formulations and diverse patient populations.
Authors
- Ke Wang (ORCID: https://orcid.org/0000-0003-1030-0288)
- Xiaoxi Li (ORCID: https://orcid.org/0000-0001-9338-9497)
- Zhizhou Wang
- Xiaotong Zhang (ORCID: https://orcid.org/0009-0007-6723-1195)
- Lan Zhang (ORCID: https://orcid.org/0000-0002-9047-2006)
- Zhichao Zhang (ORCID: https://orcid.org/0000-0001-7990-101X)
- Xiaoxuan Xing
- Xin Hu (ORCID: https://orcid.org/0000-0002-0270-1922)
- Chao Wu (ORCID: https://orcid.org/0009-0007-7251-8094)
- Xian‐Zhe Dong (ORCID: https://orcid.org/0000-0002-5286-4623)
- Yingnan Feng
- Yi‐Ming Hua (ORCID: https://orcid.org/0000-0002-0434-1983)
Institutions
- Zunyi Medical University (CN)
- Capital Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3389/fphar.2025.1528633
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wu Jieping Medical Foundation